PT3806955T - Agonistas dos receptores glp-1 e suas utilizações - Google Patents
Agonistas dos receptores glp-1 e suas utilizaçõesInfo
- Publication number
- PT3806955T PT3806955T PT197331515T PT19733151T PT3806955T PT 3806955 T PT3806955 T PT 3806955T PT 197331515 T PT197331515 T PT 197331515T PT 19733151 T PT19733151 T PT 19733151T PT 3806955 T PT3806955 T PT 3806955T
- Authority
- PT
- Portugal
- Prior art keywords
- glp
- receptor agonists
- agonists
- receptor
- Prior art date
Links
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/40—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/02—Formic acid
- C07C53/06—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/08—Acetic acid
- C07C53/10—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862684696P | 2018-06-13 | 2018-06-13 | |
| US201962846944P | 2019-05-13 | 2019-05-13 | |
| US201962851206P | 2019-05-22 | 2019-05-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3806955T true PT3806955T (pt) | 2023-07-20 |
Family
ID=67003576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT197331515T PT3806955T (pt) | 2018-06-13 | 2019-06-11 | Agonistas dos receptores glp-1 e suas utilizações |
Country Status (38)
| Country | Link |
|---|---|
| US (5) | US10934279B2 (pt) |
| EP (2) | EP4219487A1 (pt) |
| JP (1) | JP6916968B1 (pt) |
| KR (1) | KR102542199B1 (pt) |
| CN (1) | CN112533674A (pt) |
| AU (1) | AU2019285491B2 (pt) |
| BR (1) | BR112020024470A2 (pt) |
| CA (1) | CA3045644C (pt) |
| CL (1) | CL2020003222A1 (pt) |
| CO (1) | CO2020015305A2 (pt) |
| CR (1) | CR20200612A (pt) |
| CU (1) | CU20200099A7 (pt) |
| CY (1) | CY1126097T1 (pt) |
| DK (1) | DK3806955T3 (pt) |
| EC (1) | ECSP20078651A (pt) |
| ES (1) | ES2949954T3 (pt) |
| FI (1) | FI3806955T3 (pt) |
| GE (1) | GEP20237453B (pt) |
| HR (1) | HRP20230631T1 (pt) |
| HU (1) | HUE063074T2 (pt) |
| IL (1) | IL279300B2 (pt) |
| LT (1) | LT3806955T (pt) |
| MD (1) | MD3806955T3 (pt) |
| MX (1) | MX2020013625A (pt) |
| NI (1) | NI202000091A (pt) |
| NZ (1) | NZ770240A (pt) |
| PE (2) | PE20240584A1 (pt) |
| PH (1) | PH12020552069A1 (pt) |
| PL (1) | PL3806955T3 (pt) |
| PT (1) | PT3806955T (pt) |
| RS (1) | RS64323B9 (pt) |
| SG (1) | SG11202011465QA (pt) |
| SI (1) | SI3806955T1 (pt) |
| TW (1) | TWI707683B (pt) |
| UA (1) | UA124371C2 (pt) |
| UY (1) | UY38261A (pt) |
| WO (1) | WO2019239319A1 (pt) |
| ZA (1) | ZA202007572B (pt) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10934279B2 (en) * | 2018-06-13 | 2021-03-02 | Pfizer Inc. | GLP-1 receptor agonists and uses thereof |
| EP3806855B1 (en) | 2018-06-15 | 2023-03-01 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| BR112021009877A2 (pt) | 2018-11-22 | 2021-08-17 | Qilu Regor Therapeutics Inc. | agonistas glp-1r e usos dos mesmos |
| US10954221B2 (en) | 2019-04-12 | 2021-03-23 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
| CA3140972C (en) * | 2019-05-20 | 2024-06-18 | Pfizer Inc. | Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases |
| TWI751585B (zh) * | 2019-06-28 | 2022-01-01 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| KR20220092909A (ko) | 2019-10-25 | 2022-07-04 | 길리애드 사이언시즈, 인코포레이티드 | Glp-1r 조절 화합물 |
| BR112022010599A2 (pt) * | 2019-12-10 | 2022-08-16 | Pfizer | Formas sólidas de ácido 2-((4-((s)-2-(5-cloropiridin-2-il)-2-metilbenzo[d][1,3]dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il)metil)-1h-benzo[d]imidazol-6-carboxílico, sal de 1,3-dihidróxi-2-(hidroximetil)propan-2-amina |
| KR20220133271A (ko) * | 2020-01-29 | 2022-10-04 | 길리애드 사이언시즈, 인코포레이티드 | Glp-1r 조절 화합물 |
| CR20220371A (es) | 2020-02-07 | 2022-10-27 | Gasherbrum Bio Inc | Agonistas heterocíclicos de glp-1 |
| CN113493447B (zh) * | 2020-04-03 | 2024-06-11 | 轩竹(北京)医药科技有限公司 | Glp-1受体激动剂 |
| TW202144340A (zh) * | 2020-04-03 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用 |
| WO2021219019A1 (en) | 2020-04-29 | 2021-11-04 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2021249492A1 (zh) * | 2020-06-10 | 2021-12-16 | 南京明德新药研发有限公司 | 甲基取代的苯并二噁唑类化合物及其应用 |
| WO2021254470A1 (zh) * | 2020-06-19 | 2021-12-23 | 江苏恒瑞医药股份有限公司 | 6-氧代-3,6-二氢吡啶类衍生物、其制备方法及其在医药上的应用 |
| CN113816948B (zh) * | 2020-06-19 | 2023-08-11 | 江苏恒瑞医药股份有限公司 | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 |
| IL300155A (en) | 2020-08-06 | 2023-03-01 | Gasherbrum Bio Inc | Heterocyclic GLP-1 agonists |
| TW202214622A (zh) * | 2020-08-06 | 2022-04-16 | 大陸商上海齊魯銳格醫藥研發有限公司 | Ｇｌｐ－１ｒ促效劑及其用途 |
| JP2023538949A (ja) | 2020-08-28 | 2023-09-12 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| CN115884969A (zh) * | 2020-09-01 | 2023-03-31 | 江苏恒瑞医药股份有限公司 | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 |
| WO2022068772A1 (zh) * | 2020-09-29 | 2022-04-07 | 深圳信立泰药业股份有限公司 | 一种苯并咪唑类衍生物及其制备方法和医药用途 |
| CN116547279A (zh) * | 2020-10-13 | 2023-08-04 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| CN114478694A (zh) * | 2020-11-13 | 2022-05-13 | 成都奥达生物科技有限公司 | 一种长效mc4r激动剂 |
| EP4247804A1 (en) | 2020-11-20 | 2023-09-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| MX2023006186A (es) | 2020-11-27 | 2023-08-07 | Shenzhen Salubris Pharm Co Ltd | Derivado de benzimidazol y método de preparación del mismo y uso médico del mismo. |
| CN114591308B (zh) * | 2020-12-03 | 2024-03-08 | 苏州闻泰医药科技有限公司 | 一类glp-1r受体激动剂化合物及其用途 |
| US12065434B2 (en) | 2020-12-15 | 2024-08-20 | Pfizer Inc. | Metabolites of GLP1R agonists |
| AU2022212019A1 (en) * | 2021-01-28 | 2023-08-03 | Carmot Therapeutics, Inc. | Gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use |
| WO2022184849A1 (en) | 2021-03-04 | 2022-09-09 | Les Laboratoires Servier | Glp-1r agonists, uses and pharmaceutical compositions thereof |
| WO2022192428A1 (en) | 2021-03-11 | 2022-09-15 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| WO2022202864A1 (ja) | 2021-03-24 | 2022-09-29 | 塩野義製薬株式会社 | 縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物 |
| WO2022219495A1 (en) | 2021-04-12 | 2022-10-20 | Novartis Ag | 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity |
| US11858918B2 (en) | 2021-04-21 | 2024-01-02 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
| CN117177970A (zh) * | 2021-04-30 | 2023-12-05 | 上海翰森生物医药科技有限公司 | 多环类衍生物调节剂、其制备方法和应用 |
| AU2022271223A1 (en) * | 2021-05-03 | 2023-11-02 | Carmot Therapeutics, Inc. | Benzimidazoyl glp-1 receptor agonists, pharmaceutical compositions comprising the same, and methods for their use |
| TWI843104B (zh) | 2021-05-20 | 2024-05-21 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| CN117715906A (zh) * | 2021-07-21 | 2024-03-15 | 和博医药有限公司 | 胰高血糖素样肽-1受体调节剂及其用途 |
| CN113480534B (zh) * | 2021-07-23 | 2022-05-13 | 广州必贝特医药股份有限公司 | 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用 |
| MX2024001331A (es) * | 2021-08-04 | 2024-04-19 | Shanghai Hansoh Biomedical Co Ltd | Regulador derivado del cicloalqueno, método de preparación de este y su aplicación. |
| AU2022333115A1 (en) * | 2021-08-24 | 2024-04-04 | Dongbao Purple Star (Hangzhou) Biopharmaceutical Co., Ltd. | Imidazocyclic compound and application thereof |
| AU2022344074A1 (en) | 2021-09-08 | 2024-02-29 | Shionogi & Co., Ltd. | Medicine for prevention and treatment of diseases linked to anti-obesity activity |
| WO2023057427A1 (en) * | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes as glp-1 receptor modulators |
| WO2023057429A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| WO2023057414A1 (en) * | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| CN115991685A (zh) | 2021-10-20 | 2023-04-21 | 韶远科技（上海)有限公司 | 一种氧杂环丁烷-2-甲胺的制备方法 |
| AU2022375634A1 (en) | 2021-10-25 | 2024-06-06 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| JPWO2023106310A1 (pt) * | 2021-12-07 | 2023-06-15 | ||
| CN113974618B (zh) * | 2021-12-12 | 2022-09-13 | 广西澍源智能科技有限公司 | 基于水峰血糖修正的无创血糖测试方法 |
| WO2023111144A1 (en) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| WO2023111145A1 (en) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| WO2023116879A1 (zh) * | 2021-12-23 | 2023-06-29 | 江苏恒瑞医药股份有限公司 | 一种glp-1受体激动剂的结晶形式及其制备方法 |
| KR20240125003A (ko) * | 2021-12-23 | 2024-08-19 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | Glp-1 수용체 작용제의 약학적으로 허용 가능한 염, 결정 형태 및 이의 제조방법 |
| CN116354945B (zh) * | 2021-12-27 | 2024-08-30 | 长春金赛药业有限责任公司 | 一种稠合咪唑羧酸类化合物及其制备方法和应用 |
| WO2023151574A1 (en) * | 2022-02-09 | 2023-08-17 | Gasherbrum Bio Inc. | Heterocyclic glp-1 agonists |
| WO2023151575A1 (en) * | 2022-02-09 | 2023-08-17 | Gasherbrum Bio Inc. | Heterocyclic glp-1 agonists |
| TW202342014A (zh) | 2022-02-10 | 2023-11-01 | 瑞士商諾華公司 | １，３－苯并二氧戊環衍生物 |
| AU2023225875A1 (en) * | 2022-02-28 | 2024-09-26 | Ascletis Bioscience Co., Ltd. | Glp-1r modulating compounds |
| WO2023169436A1 (zh) * | 2022-03-08 | 2023-09-14 | 广州市联瑞制药有限公司 | 苯并双环类化合物及其制备方法和应用 |
| WO2023228023A1 (en) | 2022-05-23 | 2023-11-30 | Pfizer Inc. | Treatment of type 2 diabetes or weight management control with 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d]imidazole-6-carboxylic acid or a pharmaceutically salt thereof |
| WO2024051749A1 (zh) * | 2022-09-06 | 2024-03-14 | 德睿智药(苏州)新药研发有限公司 | 一种glp-1r激动剂化合物的多晶型物及其制备方法与用途 |
| WO2024063143A1 (ja) * | 2022-09-22 | 2024-03-28 | 塩野義製薬株式会社 | Ｇｌｐ－１受容体アゴニスト作用を有する縮合環化合物 |
| WO2024102625A1 (en) | 2022-11-11 | 2024-05-16 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
| WO2024107781A1 (en) | 2022-11-16 | 2024-05-23 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
| WO2024160271A1 (zh) * | 2023-02-02 | 2024-08-08 | 江苏豪森药业集团有限公司 | 一种环烯类化合物的盐、晶型及其制备方法和应用 |
| USD1011080S1 (en) | 2023-07-28 | 2024-01-16 | Voilasophy, Llc. | Yoga storage rack |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| EP0689535B1 (en) | 1993-03-18 | 1998-09-23 | MERCK SHARP & DOHME LTD. | Benzimidazole derivatives |
| AR022303A1 (es) | 1999-01-22 | 2002-09-04 | Lundbeck & Co As H | Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion |
| JP2003512422A (ja) | 1999-10-29 | 2003-04-02 | メルク シャープ エンド ドーム リミテッド | ベンズイミダゾールｎｍｄａ／ｎｒ２ｂアンタゴニストを使用する疼痛の治療方法 |
| WO2002055496A1 (en) | 2001-01-15 | 2002-07-18 | Glaxo Group Limited | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression |
| US7160879B2 (en) * | 2002-01-10 | 2007-01-09 | Neurogen Corporation | Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1H-benzoimidazole analogues |
| US20040127504A1 (en) | 2002-09-06 | 2004-07-01 | Cowart Marlon D. | Benzimidazoles that are useful in treating sexual dysfunction |
| MY140489A (en) | 2003-12-26 | 2009-12-31 | Eisai R&D Man Co Ltd | 1,2-di (cyclic) substituted benzene compounds |
| GB0412467D0 (en) | 2004-06-04 | 2004-07-07 | Astrazeneca Ab | Chemical compounds |
| WO2008012623A1 (en) | 2006-07-25 | 2008-01-31 | Pfizer Products Inc. | Benzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor |
| MA33219B1 (fr) * | 2009-03-30 | 2012-04-02 | Transtech Pharma Inc | Derives d'azoanthracene substitues, compositions pharmaceutiques et leurs procedes d'utilisation |
| CH702192A1 (de) | 2009-11-04 | 2011-05-13 | New Dent Ag | Keramisches Implantat. |
| WO2011097491A1 (en) | 2010-02-04 | 2011-08-11 | Glaxosmithkline Llc | Benzimidazole antiviral agents |
| SG185515A1 (en) | 2010-05-13 | 2012-12-28 | Amgen Inc | Nitrogen heterocyclic compounds useful as pde10 inhibitors |
| US8859577B2 (en) | 2010-09-30 | 2014-10-14 | Pfizer Inc. | N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors |
| CU24152B1 (es) | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| JP2016513112A (ja) | 2013-02-18 | 2016-05-12 | ザ スクリプス リサーチ インスティテュート | 治療的潜在能力を有するバソプレッシン受容体のモジュレーター |
| WO2016029146A1 (en) | 2014-08-22 | 2016-02-25 | University Of Washington | Specific inhibitors of methionyl-trna synthetase |
| CA3001857A1 (en) | 2015-10-14 | 2017-04-20 | Aquinnah Pharmaceuticals, Inc. | Compounds, compositions and methods of use against stress granules |
| HUE054380T2 (hu) | 2015-12-29 | 2021-09-28 | Pfizer | Helyettesített 3-azabiciklo[3.1.0]hexánok mint ketohexokináz inhibitorok |
| AR109179A1 (es) | 2016-08-19 | 2018-11-07 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
| JOP20190060A1 (ar) | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
| CN106271089B (zh) | 2016-09-30 | 2019-01-25 | 英诺激光科技股份有限公司 | 一种激光薄膜刻蚀装置及方法 |
| US10934279B2 (en) * | 2018-06-13 | 2021-03-02 | Pfizer Inc. | GLP-1 receptor agonists and uses thereof |
| CA3140972C (en) * | 2019-05-20 | 2024-06-18 | Pfizer Inc. | Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases |
-
2019
- 2019-06-10 US US16/436,311 patent/US10934279B2/en active Active
- 2019-06-10 CA CA3045644A patent/CA3045644C/en active Active
- 2019-06-10 TW TW108119890A patent/TWI707683B/zh active
- 2019-06-11 MD MDE20210363T patent/MD3806955T3/ro unknown
- 2019-06-11 CN CN201980053632.5A patent/CN112533674A/zh active Pending
- 2019-06-11 HU HUE19733151A patent/HUE063074T2/hu unknown
- 2019-06-11 GE GEAP201915517A patent/GEP20237453B/en unknown
- 2019-06-11 SG SG11202011465QA patent/SG11202011465QA/en unknown
- 2019-06-11 DK DK19733151.5T patent/DK3806955T3/da active
- 2019-06-11 PE PE2023003553A patent/PE20240584A1/es unknown
- 2019-06-11 SI SI201930570T patent/SI3806955T1/sl unknown
- 2019-06-11 MX MX2020013625A patent/MX2020013625A/es unknown
- 2019-06-11 LT LTEPPCT/IB2019/054867T patent/LT3806955T/lt unknown
- 2019-06-11 PL PL19733151.5T patent/PL3806955T3/pl unknown
- 2019-06-11 BR BR112020024470-8A patent/BR112020024470A2/pt unknown
- 2019-06-11 JP JP2020569190A patent/JP6916968B1/ja active Active
- 2019-06-11 CU CU2020000099A patent/CU20200099A7/es unknown
- 2019-06-11 IL IL279300A patent/IL279300B2/en unknown
- 2019-06-11 CR CR20200612A patent/CR20200612A/es unknown
- 2019-06-11 PT PT197331515T patent/PT3806955T/pt unknown
- 2019-06-11 PE PE2020001993A patent/PE20211601A1/es unknown
- 2019-06-11 NZ NZ770240A patent/NZ770240A/en unknown
- 2019-06-11 AU AU2019285491A patent/AU2019285491B2/en active Active
- 2019-06-11 UA UAA202007608A patent/UA124371C2/uk unknown
- 2019-06-11 HR HRP20230631TT patent/HRP20230631T1/hr unknown
- 2019-06-11 RS RS20230504A patent/RS64323B9/sr unknown
- 2019-06-11 ES ES19733151T patent/ES2949954T3/es active Active
- 2019-06-11 EP EP23155747.1A patent/EP4219487A1/en active Pending
- 2019-06-11 EP EP19733151.5A patent/EP3806955B9/en active Active
- 2019-06-11 FI FIEP19733151.5T patent/FI3806955T3/fi active
- 2019-06-11 WO PCT/IB2019/054867 patent/WO2019239319A1/en unknown
- 2019-06-11 KR KR1020217000940A patent/KR102542199B1/ko active IP Right Grant
- 2019-06-12 UY UY0001038261A patent/UY38261A/es unknown
- 2019-08-08 US US16/535,616 patent/US10676465B2/en active Active
- 2019-08-08 US US16/535,553 patent/US10683281B2/en active Active
-
2020
- 2020-12-01 NI NI202000091A patent/NI202000091A/es unknown
- 2020-12-02 PH PH12020552069A patent/PH12020552069A1/en unknown
- 2020-12-04 EC ECSENADI202078651A patent/ECSP20078651A/es unknown
- 2020-12-04 ZA ZA2020/07572A patent/ZA202007572B/en unknown
- 2020-12-07 CO CONC2020/0015305A patent/CO2020015305A2/es unknown
- 2020-12-11 CL CL2020003222A patent/CL2020003222A1/es unknown
-
2021
- 2021-02-09 US US17/171,385 patent/US20210163455A1/en not_active Abandoned
-
2023
- 2023-07-19 CY CY20231100347T patent/CY1126097T1/el unknown
- 2023-10-09 US US18/483,311 patent/US20240059679A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279300A (en) | 1-GLP agonist receptors and their use | |
| IL279224A (en) | 1-GLP agonist receptors and their use | |
| ZA201904616B (en) | Glp-1 receptor agonists and uses thereof | |
| IL283322A (en) | glp-1r agonists and uses thereof | |
| EP3807267A4 (en) | THYROID HORMONE RECEPTOR AGONISTS AND ASSOCIATED USES | |
| EP4059929A4 (en) | GLP-1 RECEPTOR AGONIST AND ITS USE | |
| EP3463429A4 (en) | PARTIAL INSULIN RECEPTOR AGONISTS AND GLP-1 ANALOGUES | |
| IL281475A (en) | Paranoid X receptor agonists and uses thereof | |
| IL281471A (en) | Farnesoid x receptor agonists and uses thereof | |
| IL281474A (en) | Farnesoid x receptor agonists and uses thereof | |
| IL304574A (en) | Glucagon-like peptide-1 receptor agonists and their uses | |
| EP3445769A4 (en) | THYROID HORMONE RECEPTOR AGONIST AND ITS USE | |
| GB201811757D0 (en) | Composition comprising GLP-1 receptor agonist and glucagon receptor agonist and application thereof | |
| ZA202209312B (en) | Glp-1r agonists and uses thereof | |
| GB201817943D0 (en) | Galanin-2 receptor agonists | |
| GB201816650D0 (en) | GLP-1 Receptor antagonists |